Sevilla

• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending
  2024-515448-22-00 4 Parkinson
• Study to assess the safety and efficacy of multipotent mesenchymal stem cells administration as a treatment for patients with faecal inconti … Pending
  2024-515766-13-00 4 Fecal incontinence
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab … Pending
  2024-516236-10-00 4 Triple-negative breast cancer
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP … Pending
  2024-516570-30-00 4 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
• A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02 … Pending
  2024-517339-30-00 7 Advanced Solid Tumors
• A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's … Pending
  2024-517388-22-00 10 Agitation in Alzheimer's Disease Dementia
• MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study Pending
  2024-517600-11-01 5 Acute ischemic stroke
• Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma pat … Pending
  2024-518199-30-00 9 Soft tissue sarcoma patients
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Pending
  2024-518326-32-00 7 Patients with advanced solid malignancies that have progressed followi
• REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending
  2024-519298-21-00 5 Cancer-Associated Thrombosis (CAT).
• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl … Pending
  2024-519638-22-00 5 IgA nephropathy
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Pending
  2024-519818-31-01 5 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending
  2024-520218-23-00 10 Pulmonary Arterial Hypertension
• Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Pending
  2025-520471-29-00 5 Locally advanced adenocarcinoma of the colon and upper rectum with mic
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC Pending
  2025-521130-28-00 5 generalized myasthenia gravis
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer

Showing 25–48 of 1,630 trials